- The AbbVie patient assistance program, myAbbVie Assist, can provide AbbVie specialty medicines free to qualifying uninsured and underinsured patients — it is an affordability program, not insurance.
- Covered medicines have historically included Humira, Rinvoq, Skyrizi, Mavyret, Qulipta, Ubrelvy, Vraylar, Linzess, Creon and others; the list changes, so confirm your specific medication is covered.
- Income limits are generous — reportedly up to about 600% of the Federal Poverty Level for many products (roughly $95,760 for one person or $198,000 for a family of four in 2026) — but they vary by drug and change annually, so verify the current criteria.
- Applications are prescriber-directed: your physician must complete the clinical section and sign, and you provide proof of income; approval typically lasts up to 12 months before you must reapply.
- Medicare Part D patients face extra rules (for example, showing an Extra Help denial when income is low) and often do better with nonprofit copay foundations and the 2026 Medicare Prescription Payment Plan.
- Apply at myAbbVieAssist.com or by phone, and if you have commercial insurance, compare AbbVie's $5 copay savings cards, which can be a better fit than the assistance program.
AbbVie manufactures some of the most expensive specialty drugs in America, including Humira, Rinvoq, Skyrizi, and Ubrelvy, and the AbbVie patient assistance program exists to provide many of those medications free of charge to patients who qualify. The program, officially called myAbbVie Assist, is income-based and serves uninsured patients along with some insured patients facing catastrophic out-of-pocket costs. Given that a biologic like Humira has historically listed for tens of thousands of dollars a year, the stakes are high. Program details and income limits change over time, so treat the figures below as a starting point and verify current terms before applying. Our healthcare costs guide covers more prescription relief strategies if you want context first.
This article is independent educational information. FMHC is not affiliated with, endorsed by, or sponsored by AbbVie, and we do not administer myAbbVie Assist.
What myAbbVie Assist Actually Provides
myAbbVie Assist is not a coupon or a cash discount. It is a traditional patient assistance program that ships free medication to qualifying patients or to their prescriber’s office on a rolling basis. AbbVie funds the program directly, which means approval is based on AbbVie’s published criteria rather than third-party verification. It is free to apply, and patients who qualify generally receive their medicine at no cost, with no copays or shipping fees.
Covered medications have included much of the company’s specialty portfolio — for example Humira, Rinvoq, Skyrizi, Mavyret, Venclexta, Imbruvica, Ubrelvy, Qulipta, Vraylar, Viberzi, Linzess, Creon, and several oncology products, among others. AbbVie updates the covered-product list over time (newer additions such as Elahere and Emrelis have appeared, while individual products can move on or off), so confirm that your specific medication is currently covered before you rely on it. AbbVie typically ships a 90-day supply at a time, with renewals based on continued need and income eligibility.
Who Qualifies for the AbbVie Patient Assistance Program
AbbVie sets several primary eligibility criteria, and applicants generally must meet all of them. First, you must be a U.S. resident being treated on an outpatient basis with a valid prescription from a licensed U.S. health care provider for an AbbVie medicine in the program. Second, your household income must fall within AbbVie’s published thresholds, which vary by product and are updated annually — for many branded specialty drugs the ceiling is reported to be as high as about 600% of the federal poverty level. For 2026, 600% of FPL is roughly $95,760 for a single-person household and about $198,000 for a family of four, based on the HHS poverty guidelines; treat these as illustrative and verify the current limit for your drug.
Third, you must be uninsured or have an unmet financial need that your insurance does not cover. Commercially insured patients can sometimes qualify if they have exhausted copay assistance cards and face hardship due to high deductibles. Medicare Part D patients may apply in specific circumstances, but AbbVie applies extra rules — for example, patients with income under 150% of the FPL are generally asked to provide proof of denial from the Medicare Extra Help (Low-Income Subsidy) program before being evaluated for assistance. Fourth, Medicaid enrollees are generally not eligible because Medicaid already covers AbbVie drugs at reduced prices.
Income Thresholds by Drug Category
AbbVie does not publish a single income table for all drugs. Instead, each medication has its own ceiling, and the company updates these annually. Immunology drugs such as Humira, Rinvoq, and Skyrizi have typically used the most generous threshold, around 600% FPL. Migraine drugs (Ubrelvy, Qulipta) have often used a lower cap, and oncology drugs may use different thresholds given the seriousness of the conditions and the cost of treatment. Because these tiers change, do not assume a category’s limit — check the figure for your exact medication.
You can verify the current threshold for your specific medication at myAbbVieAssist.com or by calling 1-800-222-6885. AbbVie’s eligibility team will ask for recent tax returns or pay stubs as part of the verification process.
How to Apply for myAbbVie Assist
The application process has three main steps and typically takes a few weeks from submission to first medication shipment. Begin by visiting myAbbVieAssist.com and selecting your medication, or call 1-800-222-6885 to request a paper application by mail. Complete the patient section with demographic information, household size, income, and current insurance status.
Your prescribing physician completes the prescriber section with your diagnosis, the medication, dosing, and duration of treatment. A physician signature is mandatory — this is a prescriber-directed program. AbbVie also requires proof of income, usually a copy of your most recent IRS Form 1040 or recent pay stubs. If you have no documentable income, AbbVie generally accepts a signed letter explaining your financial situation.
Submit the completed application by the method AbbVie specifies (secure online portal, fax, or mail). AbbVie reviews the application, may request additional documentation, and notifies you and your prescriber of the decision. Approved patients typically receive their first shipment within roughly a few weeks of approval. Because fax numbers, timelines, and forms can change, confirm the current process on AbbVie’s site or by phone.
What You Get After Approval
Approved patients typically receive a 90-day supply of their medication, shipped to the prescriber’s office or, for self-administered biologics such as Humira, Rinvoq, and Skyrizi, often directly to the patient’s home in temperature-controlled packaging. Approval generally lasts up to 12 months, after which you must reapply and resubmit income verification.
AbbVie does not charge any fees for the medication or shipping. The program operates through AbbVie’s corporate patient access infrastructure rather than third-party pharmacies.
Alternatives If You Don’t Qualify
Patients who exceed the income threshold or who have insurance coverage often receive more value from AbbVie’s commercial copay cards. The Humira Complete Savings Card can drop eligible commercially insured patients to as little as $5 per month, and the Rinvoq Complete and Skyrizi Complete programs offer similar low copays. These savings cards cannot be used by patients with Medicare, Medicaid, Tricare, or VA coverage.
Medicare Part D patients excluded from copay cards can look to the Medicare Prescription Payment Plan (M3P), which lets you spread your out-of-pocket costs over the calendar year in monthly installments; in 2026 total covered out-of-pocket spending under Part D is capped at $2,100, after which your plan pays 100% of covered drugs for the rest of the year. Beneficiaries already enrolled in M3P are automatically re-enrolled each year starting in 2026. Nonprofit foundations including the PAN Foundation, HealthWell Foundation, and Good Days also maintain disease-specific funds that may cover AbbVie drug copays for Medicare and commercially insured patients when a fund is open. Our NovoCare PAP guide and Novartis PAP guide cover comparable programs from other manufacturers.
Frequently Asked Questions
Is the AbbVie patient assistance program free?
For those who qualify, yes. Qualifying patients receive their medication at no cost, and there are no application or processing fees. AbbVie funds the program directly and ships medication free of charge.
How long does it take to get approved for myAbbVie Assist?
Most complete applications are processed within a few weeks, though timelines change. Incomplete applications, missing income documentation, or a missing physician signature can extend the timeline. Call 1-800-222-6885 if you have not heard back within about 30 days.
Can Medicare patients use the AbbVie patient assistance program?
Sometimes, but only in specific circumstances. Medicare Part D patients typically must demonstrate financial hardship, and lower-income applicants may be asked to show they were denied Extra Help before AbbVie evaluates them. Many Medicare patients have more success with nonprofit copay foundations and the Medicare Prescription Payment Plan.
Does myAbbVie Assist cover Humira biosimilars?
Humira biosimilars are manufactured by competing companies (Amgen, Sandoz, Boehringer Ingelheim, and others), so myAbbVie Assist does not cover them. If your doctor has switched you to a biosimilar, look up that manufacturer’s separate patient assistance program.
Do I need to reapply every year?
Yes. AbbVie requires annual reenrollment with updated income verification. The company generally sends reminder notices before your current enrollment expires, but do not rely solely on a reminder — track your renewal date yourself.
The Bottom Line
The AbbVie patient assistance program, myAbbVie Assist, can provide free Humira, Rinvoq, Skyrizi, and other AbbVie specialty medications to qualifying uninsured and underinsured patients, with income limits reported to reach as high as about 600% of the federal poverty level for many drugs. Because covered products and income rules change, confirm both for your specific medication. Apply online at myAbbVieAssist.com or call 1-800-222-6885, coordinate with your prescribing physician, and submit proof of income. Insured patients should compare AbbVie’s commercial copay cards, and Medicare patients should explore nonprofit foundations and the 2026 M3P payment plan.
Patient assistance programs and savings cards are affordability programs, not health insurance, and this article is general education, not medical or financial advice. Covered products, eligibility rules, income thresholds, and prices change often and vary by drug and plan. FMHC is not affiliated with AbbVie. Verify current terms directly with myAbbVie Assist before you rely on any figure here, and talk to your prescriber about the right treatment for you.
Sources
- AbbVie / myAbbVie Assist (AbbVie.com Patient Access Support) — eligibility, covered products, income criteria, application steps, phone 1-800-222-6885
- AbbVie — Medicare Part D income and Extra Help rule for patient assistance evaluation
- HHS — 2026 Federal Poverty Level guidelines (600% FPL figures)
- CMS / Medicare.gov — 2026 Medicare Part D out-of-pocket cap ($2,100) and the Medicare Prescription Payment Plan (M3P)
- Nonprofit copay foundations — PAN Foundation, HealthWell Foundation, and Good Days (disease-specific assistance funds)